Skip to main content

Table 5 Additional information about normocomplementemic (Normo-C) and hypocomplementemic (Hypo-C) groups

From: Higher interferon score and normal complement levels may identify a distinct clinical subset in children with systemic lupus erythematosus

    Normo-C group Hypo-C group
Never Hypo-C Previously Hypo-C
Treatment at sample collection time Prednisone (mg/day) Mean 15.1 2.0 19.3
Median 7.5 0 15.0
SD 16.9 2.7 14.4
Hydroxychloroquine (mg/day) Mean 296.4 310.0 250.0
Median 300.0 300.0 225.0
SD 104.6 89.4 108.7
SLICC Damage Index Mean 0.4 0 0.9
Median 0 0 0
SD 0.5 0 1.4
BILAG-2004 Mean 4.1 3.0 11.9
Median 2.5 2.0 9.5
SD 4.8 3.3 9.8
Age at diagnosis (years) Mean 12 14 10
Median 12 14 10
SD 3 3 2
Age at sample collection time (years) Mean 14 15 13
Median 13 15 14
SD 3 3 4
Disease duration (years) Mean 5 4 6
Median 4 5 5
SD 2 2 3
Complement follow-up Months Mean 23 21 32
Median 15 22 20
SD 27 13 28
No. of measurement (until sample collection time) Mean 4 4 6
Median 3 3 6
SD 4 2 4
  1. The normocomplementemic (Normo-C) group has been divided into two subgroups: the “Never Hypo-C” and the “Previously Hypo-C”. Multiple comparisons were performed with Kruskal-Wallis non-parametric test. P values < 0.05 were considered significant (*p < 0.05). SD standard deviation